DK0617124T3 - Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster - Google Patents
Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulsterInfo
- Publication number
- DK0617124T3 DK0617124T3 DK94109426T DK94109426T DK0617124T3 DK 0617124 T3 DK0617124 T3 DK 0617124T3 DK 94109426 T DK94109426 T DK 94109426T DK 94109426 T DK94109426 T DK 94109426T DK 0617124 T3 DK0617124 T3 DK 0617124T3
- Authority
- DK
- Denmark
- Prior art keywords
- diagnosis
- treatment
- malignant tumors
- immune reactivity
- malignancy
- Prior art date
Links
- 201000011510 cancer Diseases 0.000 title abstract 5
- 108700020796 Oncogene Proteins 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 102000043276 Oncogene Human genes 0.000 title 1
- 230000009257 reactivity Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 5
- 230000036210 malignancy Effects 0.000 abstract 4
- 238000001514 detection method Methods 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Zoology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47064590A | 1990-01-26 | 1990-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0617124T3 true DK0617124T3 (da) | 1999-12-06 |
Family
ID=23868429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94109426T DK0617124T3 (da) | 1990-01-26 | 1991-01-24 | Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster |
Country Status (10)
Country | Link |
---|---|
US (5) | US5320947A (es) |
EP (2) | EP0617124B1 (es) |
JP (3) | JP2552047B2 (es) |
AT (2) | ATE120860T1 (es) |
AU (1) | AU639311B2 (es) |
CA (1) | CA2074720C (es) |
DE (2) | DE69108716T2 (es) |
DK (1) | DK0617124T3 (es) |
ES (2) | ES2070492T3 (es) |
WO (1) | WO1991011719A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2011099A1 (en) * | 1989-04-19 | 1990-10-19 | Stephen C. Wardlaw | Determination of lymphocyte reactivity to specific antigens in blood |
ES2070492T3 (es) * | 1990-01-26 | 1995-06-01 | Washington Res Found | Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos. |
GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
WO1993006248A1 (en) * | 1991-09-16 | 1993-04-01 | The United States Of America Represented By The Secretary, Department Of Health & Human Services | Detection method for c-raf-1 genes |
US5512473A (en) * | 1993-01-29 | 1996-04-30 | Brent; Roger | Max-interacting proteins and related molecules and methods |
US5801005A (en) * | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5869445A (en) * | 1993-03-17 | 1999-02-09 | University Of Washington | Methods for eliciting or enhancing reactivity to HER-2/neu protein |
US6953573B1 (en) * | 1993-03-17 | 2005-10-11 | University Of Washington | Compounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated |
US5419900A (en) | 1993-05-19 | 1995-05-30 | The United States Of America As Represented By The Department Of Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US6156316A (en) * | 1995-05-08 | 2000-12-05 | Sloan-Kettering Institute For Cancer Research | Oncogene fusion protein peptide vaccines |
US6942862B2 (en) * | 1996-04-01 | 2005-09-13 | University Of Washington | Methods and compositions to generate immunity in humans against self tumor antigens by immunization with homologous foreign proteins |
AU5587998A (en) | 1996-11-15 | 1998-06-03 | Cornell Research Foundation Inc. | Activated ras interaction assay |
DE19736691A1 (de) * | 1997-08-22 | 1999-02-25 | Michael Prof Dr Med Giesing | Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen |
US6551780B1 (en) * | 2000-03-31 | 2003-04-22 | The Regents Of University Of California | Detection of gene mutations or amplifications in melanocytic neoplasms |
JP4658423B2 (ja) * | 1999-08-03 | 2011-03-23 | ザ オハイオ ステイト ユニバーシティ | Her−2タンパク質に対する免疫反応性を増強するためのポリペプチドおよびポリヌクレオチド |
CA2395136A1 (en) * | 1999-12-22 | 2001-06-28 | The Scripps Research Institute | Angiogenesis and vascular permeability modulators and inhibitors |
GB0007088D0 (en) * | 2000-03-23 | 2000-05-17 | Torsana A S | Detection of immunological memory determining the position of loci of pathologyand therapeutic t-cell conjugates |
US6772026B2 (en) | 2000-04-05 | 2004-08-03 | Therics, Inc. | System and method for rapidly customizing design, manufacture and/or selection of biomedical devices |
US20030119079A1 (en) * | 2001-09-19 | 2003-06-26 | The Regents Of The University Of Michigan | Detection and treatment of cancers of the breast |
US20040076978A1 (en) * | 2001-11-14 | 2004-04-22 | Catherine Verfaillie | Method to identify genes associated with chronic myelogenous leukemia |
WO2005003821A2 (en) * | 2003-06-03 | 2005-01-13 | Bay Materials Llc | Phase change sensor |
EP1851339B1 (en) | 2005-02-11 | 2016-05-18 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for detecting a drug resistant egfr mutant |
ES2531483T3 (es) * | 2005-06-15 | 2015-03-16 | The Ohio State University Research Foundation | Péptidos HER-2 |
EP2671954B1 (en) * | 2006-01-20 | 2018-05-16 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
US8383799B2 (en) | 2006-01-20 | 2013-02-26 | Cell Signaling Technology, Inc. | Translocation and mutant ROS kinase in human non-small cell lung carcinoma |
US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
WO2007101227A2 (en) * | 2006-02-27 | 2007-09-07 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Identification and use of novopeptides for the treatment of cancer |
US8171270B2 (en) * | 2006-12-29 | 2012-05-01 | Intel Corporation | Asynchronous control transfer |
US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
CA3065325A1 (en) | 2017-06-02 | 2018-12-06 | Arizona Board Of Regents On Behalf Of Arizona State University | A method to create personalized cancer vaccines |
US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4411990A (en) * | 1979-06-13 | 1983-10-25 | University Patents, Inc. | Primary bioassay of human tumor stem cells |
US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4643968A (en) * | 1981-01-29 | 1987-02-17 | Massachusetts Institute Of Technology | Process for determining metabolism and growth of cells under various conditions |
CA1219232A (en) * | 1983-08-17 | 1987-03-17 | Richard A. Lerner | Polypeptide-induced monoclonal receptors to protein ligands |
JPS62103573A (ja) * | 1985-08-21 | 1987-05-14 | オンコジ−ン・サイエンス・インコ−ポレ−テツド | Rasがコ−ドしているタンパク質の検出用イムノアツセイ |
JPH076982B2 (ja) * | 1985-11-06 | 1995-01-30 | 株式会社ニチレイ | 抗 体 |
WO1987006940A1 (en) * | 1986-05-06 | 1987-11-19 | The Regents Of The University Of California | ASSAYS AND ANTIBODIES FOR N-myc PROTEINS |
US4820631A (en) * | 1986-07-30 | 1989-04-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Deletion mutants and monoclonal antibodies against ras proteins |
US4861589A (en) * | 1987-03-23 | 1989-08-29 | Trustees Of Boston University | Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells |
US4957859A (en) * | 1988-02-16 | 1990-09-18 | Hoffmann-La Roche Inc. | Antibodies for transforming ras protein |
ATE155813T1 (de) * | 1989-05-19 | 1997-08-15 | Genentech Inc | Her2 extrazellulare domäne |
ES2070492T3 (es) * | 1990-01-26 | 1995-06-01 | Washington Res Found | Reactividad inmunitaria para oncogenes expresados activos para diagnostico y tratamiento de estados malignos. |
-
1991
- 1991-01-24 ES ES91903946T patent/ES2070492T3/es not_active Expired - Lifetime
- 1991-01-24 DK DK94109426T patent/DK0617124T3/da active
- 1991-01-24 DE DE69108716T patent/DE69108716T2/de not_active Expired - Fee Related
- 1991-01-24 DE DE69131255T patent/DE69131255T2/de not_active Expired - Fee Related
- 1991-01-24 EP EP94109426A patent/EP0617124B1/en not_active Expired - Lifetime
- 1991-01-24 AU AU73299/91A patent/AU639311B2/en not_active Ceased
- 1991-01-24 WO PCT/US1991/000497 patent/WO1991011719A1/en active IP Right Grant
- 1991-01-24 EP EP91903946A patent/EP0513161B1/en not_active Expired - Lifetime
- 1991-01-24 JP JP3504130A patent/JP2552047B2/ja not_active Expired - Fee Related
- 1991-01-24 CA CA002074720A patent/CA2074720C/en not_active Expired - Fee Related
- 1991-01-24 ES ES94109426T patent/ES2134294T3/es not_active Expired - Lifetime
- 1991-01-24 AT AT91903946T patent/ATE120860T1/de not_active IP Right Cessation
- 1991-01-24 AT AT94109426T patent/ATE180276T1/de not_active IP Right Cessation
-
1992
- 1992-01-13 US US07/820,409 patent/US5320947A/en not_active Expired - Lifetime
-
1994
- 1994-05-31 US US08/251,590 patent/US5601989A/en not_active Expired - Lifetime
-
1995
- 1995-06-05 US US08/469,081 patent/US5773230A/en not_active Expired - Fee Related
- 1995-06-07 US US08/473,762 patent/US20030083229A1/en not_active Abandoned
-
1996
- 1996-02-29 JP JP8043483A patent/JPH08275774A/ja active Pending
-
1998
- 1998-06-16 JP JP10168736A patent/JPH1169976A/ja active Pending
-
2003
- 2003-09-24 US US10/671,328 patent/US20040235070A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ES2070492T3 (es) | 1995-06-01 |
US5773230A (en) | 1998-06-30 |
ES2134294T3 (es) | 1999-10-01 |
JP2552047B2 (ja) | 1996-11-06 |
JPH1169976A (ja) | 1999-03-16 |
EP0513161B1 (en) | 1995-04-05 |
US20040235070A1 (en) | 2004-11-25 |
ATE120860T1 (de) | 1995-04-15 |
CA2074720C (en) | 2002-07-23 |
DE69108716T2 (de) | 1995-08-17 |
DE69131255D1 (de) | 1999-06-24 |
EP0617124B1 (en) | 1999-05-19 |
DE69131255T2 (de) | 1999-12-16 |
US20030083229A1 (en) | 2003-05-01 |
US5601989A (en) | 1997-02-11 |
WO1991011719A1 (en) | 1991-08-08 |
AU639311B2 (en) | 1993-07-22 |
US5320947A (en) | 1994-06-14 |
JPH05503996A (ja) | 1993-06-24 |
DE69108716D1 (de) | 1995-05-11 |
CA2074720A1 (en) | 1991-07-27 |
JPH08275774A (ja) | 1996-10-22 |
EP0513161A1 (en) | 1992-11-19 |
EP0617124A1 (en) | 1994-09-28 |
AU7329991A (en) | 1991-08-21 |
ATE180276T1 (de) | 1999-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0617124T3 (da) | Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster | |
ES8704005A1 (es) | Un metodo para evaluar la probabilidad de malignidad celular en una muestra biologica de un haspedante humano. | |
DK0991421T3 (da) | Påvisning og modulering af IAP'er og NAIP i forbindelse med diagnose og behandling af proliferativ sygdom | |
PT99562A (pt) | Metodo para o diagnostico de tumores malignos atraves da deteccao de estromelis ina-3 | |
ATE125626T1 (de) | Cytokeratin-tumormarkierer und test zu deren nachweis. | |
TR200200937T2 (tr) | Yumurtalık kanseri tedavisi için bileşimler. | |
ATE410446T1 (de) | Zusammensetzungen zur behandlung und diagnose von eierstockkrebs | |
ES2145004T3 (es) | Derivados de anticuerpos. | |
FI963393A (fi) | Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä | |
NO830570L (no) | Antistoffer og antigener for diagnose og behandling av cancer | |
ATE178357T1 (de) | Nachweismethoden für c-raf-1-genes.5 | |
BG93995A (bg) | Хелати и комплекси на антибиотици с бивалентни и/или тривалентни метали, метод за получаването им и използването им за получаване на противоязвени средства | |
DE69021742D1 (de) | Verfahren zum Nachweis von kleinzelligem Carzinom und die Verwendung von Sequenzen, die Acylpeptid-Hydrolase codieren, für diesen zweck. | |
NO20002412D0 (no) | FremgangsmÕte for behandling av tumorer og tumorceller ved anvendelse av ex vivo aktiverte T celler | |
NO901461L (no) | Antistoffer mot retinoblastom-genprodukt og anvendelse derav. | |
DE69942637D1 (de) | Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs | |
NO970130D0 (no) | Oligomere bærermolekyler med definerte, innebygde markörgrupper og haptener | |
EP1438388A4 (en) | IBC-1 (INVASIVE-1 BREAST CANCER), ONCOGEN PRESUME AMPLIFIED IN BREAST CANCER | |
ATE132977T1 (de) | Verfahren zum nachweis von krankheiten | |
EP0341318A4 (en) | Novel platinum (ii) complex, process for preparing the same, and therapeutic agent for malignant tumor | |
IT7830722A0 (it) | Metodo di prova in vitro per la diagnosi di tumori maligni. | |
ATE49965T1 (de) | Verwendung von 2-beta-d-ribofuranosylthiazol-4carboxamiden zur herstellung von medikamenten zur behandlung von krebsartigen tumoren. | |
DE3177155D1 (de) | Verwendung von 2-beta-d-ribofuranosylthiazol-4-carboxamiden zur herstellung von medikamenten zur behandlung von krebsartigen tumoren. | |
ATE16220T1 (de) | Mittel zum nachweis der anwesenheit krebsartiger oder boesartiger tumorzellen. | |
ATE94993T1 (de) | Verfahren zur integrierten onkologischen eingangsuntersuchung und krebstherapie. |